weight loss drugs other than glp 1 Guide to FDA-Approved Comparing GLP‑1 Drugs With Other
Description
Sun F, Chai S, Yu K, et al

Five to ten percent of patients discontinued the drug across doses, the company said, which was one of two late-stage trials the drug must pass before being submitted for federal approval

Fitzgerald, K

A realistic earliest FDA decision window, assuming Phase 3 confirms the Phase 2 findings, is 2028
:max_bytes(150000):strip_icc()/Health-GLP1-pill-vs-shot-137cf589ddca421bb0aef5c5d7aec64a.png)
Yet, heterogeneity ( I 2 ) decreases significantly from 66.1% at 3 months to 0.0% at 12 months, meaning more consistency in study results over time

It is even more significant in Mounjaro (tirzepatide) which will likely be FDA approved by the end of the year for weight loss
